You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

371 Results
Guidelines and Advice
Status: Current
ID: GL 2-21
Version: 2
Mar 2024
Guidelines and Advice
Status: Current
ID: 19-5
Version: 2
Jul 2024
Guidelines and Advice
Status: Current
ID: 2-29
Version: 4
Feb 2024
Guidelines and Advice
Status: Current
ID: 8-1
Version: 6
Mar 2024
Guidelines and Advice
Status: Current
ID: GL-C50-24
Version: 3
Jan 2024
Guidelines and Advice
Status: Current
Version: 2
Jul 2024
Guidelines and Advice
Status: Current
Version: 3.1
Oct 2024
Guidelines and Advice
Status: Current
Version: 1
Nov 2024
Guidelines and Advice
Status: Current
ID: ES PET 16
Version: 2
Apr 2024
Guidelines and Advice
Status: Current
ID: GL 19-7
Mar 2024
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's High Grade, 
Lymphoma - Non-Hodgkin's Intermediate Grade
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
New Drug Funding Program
    Glofitamab (Outpatient) - Relapsed or Refractory Diffuse Large B-cell Lymphoma
High Cost Therapy Funding Program
    Glofitamab (Inpatient) - Relapsed or Refractory Diffuse Large B-cell Lymphoma
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
oBINutuzumab,
glofitamab
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Sep 2024
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's Low Grade
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
Exceptional Access Program
    zanubrutinib - For the treatment of relapsed or refractory Waldenström Macroglobulinemia, according to clinical criteria
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
zanubrutinib
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Mar 2024

Pages